Aktienanalyse zu Bolt Biotherapeutics, Inc. (BOLT)BOLTBolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in half-life-extended multispecific antibodies designed to deliver therapies. Through the proprietary INSPIRE platform, the Company combines complementary therapeutic mechanisms in fully IgG-based molecules designed for efficacy and extended exposure. Its lead program, PRA-216, is a novel IL-4Ra/TSLP bispecific antibody in Phase II development in asthma, chronic obstructive pulmonary disease, and atopic dermatitis, with a fourth Phase II study planned in eosinophilic esophagitis. In addition to PRA-216, the Company is advancing a wholly owned pipeline of additional INSPIRE-based multispecific programs across diseases with significant unmet need. Its second program is an IL-31 containing bispecific antibody being developed initially for atopic dermatitis. The Company is open to various partnering programs, including BDC-3042: P2-ready Dectin-2 Agonist mA, Preclinical CEA ISAC and Preclinical PD-L1 ISAC. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Bolt Biotherapeutics Inc is a good buy right now due to its current price of $6.54, which is significantly below the analyst price target of $22, indicating a potential upside of 236%. Additionally, the company's gross margin remains strong at 100%, suggesting that it can maintain profitability on its sales despite current losses. However, the main risk is its net income, which has been negative, with a reported loss of $7.72 million in Q2 2026, highlighting ongoing financial challenges.